

Supplemental Table 1: Differences male and female patients

	Total (n=330)	Female n=147 (44,5%)	Male n=183 (55,5%)	P value
Age, years, mean (SD)	53.3 (14.0)	53.3 (14.7)	53.3 (13.5)	0.968
BMI, kg/m ² , mean (SD)	27.3 (6.15)	27.0 (6.41)	27.5 (5.94)	0.515
Smokers, n (%) (n=311)	69 (22.2%)	33 (23.1%)	36 (21.4%)	0.727
PsA /axSpA, n (%)	168 (50.9%) / 162 (49.1%)	79 (53.7%) / 68 (46.3%)	89 (48.6%) / 94 (51.4%)	0.356
HLA B27, n (%) (n=244)	128 (52.5%)	49 (45.4%)	79 (58.1%)	0.048
Disease domains:				
Axial involvement, n (%)	220 (66.9%)	97 (66.0%)	123 (67.6%)	0.760
Peripheral arthritis, n (%)	273 (83.2%)	127 (87.6%)	146 (79.8%)	0.060
Enthesitis, n (%)	134 (40.7%)	68 (46.3%)	66 (36.3%)	0.067
Dactylitis, n (%)	84 (25.5%)	38 (25.9%)	46 (25.1%)	0.882
CRP, mg/l, mean (SD)	6.10 (11.7)	5.92 (6.04)	6.24 (14.8)	0.806
Disease duration, years, mean (SD)	11.3 (9.29)	10.6 (8.60)	11.9 (9.78)	0.209
Functional capacity (FFbH), % (n=325)	79.1 %	75.3 %	82.2%	0.003
Significant functional impairment (FFbH <60%), n (%) (n=325)	55 (17.0%)	29 (19.9%)	26 (14.6%)	0.210
Therapy:				
csDMARD, n (%)	114 (34.8%)	55 (37.7%)	59 (32.4%)	0.321
bDMARD, n (%)	224 (68.1%)	95 (64.6%)	129 (70.9%)	0.226
Anti-TNF, n (%)	144 (43.8%)	56 (38.1%)	88 (48.4%)	0.062
Anti-IL17, n (%)	66 (20.1%)	31 (21.1%)	35 (19.2%)	0.676
Glucocorticoids, n (%)	29 (8.9%)	15 (10.3%)	14 (7.8%)	0.431
NSAID monotherapy, n (%)	35 (10.6%)	17 (11.6%)	18 (9.8%)	0.612
No current therapy, n (%)	26 (7.9 %)	13 (8.8%)	13 (7.1%)	0.560
Abnormal sleep behaviour, n (%) (n=313)	146 (46.6%)	80 (55.9%)	66 (38.8%)	<0.001
Inability to sleep through the night, n (%)	154 (49.6%)	81 (56.6%)	73 (43.7%)	0.014
Waking too early, n (%)	99 (32.1%)	47 (33.1%)	52 (31.3%)	0.465
Need for sleeping pills, n (%)	20 (6.5%)	13 (9.2%)	7 (4.1%)	0.047
Unrefreshing sleep, n (%)	36 (11.6%)	25 (17.6%)	11 (6.5%)	<0.001
WHO-QOL BREF: (n=327)				
Physical HRQOL, D1, mean (SD)	60.5 (19.5)	57.6 (19.6)	62.9 (19.1)	0.015
Mental HRQOL, D2, mean (SD)	67.7 (17.3)	64.2 (17.9)	70.5 (16.3)	<0.001
Social QOL, D3, mean (SD)	68.0 (19.7)	67.4 (19.3)	68.5 (20.0)	0.623
Environmental QOL, D4, mean (SD)	77.4 (13.4)	76.7 (13.7)	78.0 (13.1)	0.377
Depressive Symptoms: (n=307)				
BDI-II score, mean (SD)	11.2 (9.4)	12.7 (9.92)	10.0 (8.78)	0.015
No depression, n (%)	142 (46.0)	56 (40.0)	86 (51.5)	} 0.019
Minimal or mild depression, n (%)	115 (37.5)	55 (39.3)	60 (35.9)	
Moderate to severe depression, n (%)	50 (16.3)	29 (20.7)	21 (12.6)	

The number (n) for individual items is given in the left column for parameters, for which data from individual patients were missing. P values refer to comparison of female and male patients. Abbreviations: SD standard deviation, n number, BMI body mass index, csDMARD conventional synthetic disease modifying antirheumatic drug, bDMARD biological DMARD, NSAID non-steroidal anti-inflammatory drug.

Supplemental Table 2: Multiple linear regression analysis of factors associated with RIS score.

SpA (whole cohort)	Predictors	β	95% CI for β	B	SE	p
	Depressive symptoms (BDI-II)	0.43	0.32 – 0.54	0.30	0.04	<0.001
Functional capacity (FFbH)	-0.21	-0.33 – -0.09	-0.07	0.02	<0.001	
Female sex	0.27	0.07 – 0.47	1.76	0.66	0.008	
Axial involvement	0.27	0.06 – 0.48	1.76	0.70	0.012	
R^2 0.378, adj. R^2 0.355, $F(10, 277) = 16.72$, $p < 0.001$ ¹						

¹Linear regression adjusted for age, disease duration, BMI, smoking status, as well as comorbidities (chronic lung disease, chronic kidney disease). Abbreviations: β standardized estimate, CI confidence interval, B estimate SE standard error.